Switch theme
Sign up to access all valuation multiples
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.
2016
1.3K+
LTM Revenue $295M
LTM EBITDA -$10.2M
$318M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Fulgent Genetics has a last 12-month revenue (LTM) of $295M and a last 12-month EBITDA of -$10.2M.
In the most recent fiscal year, Fulgent Genetics achieved revenue of $283M and an EBITDA of -$49.0M.
Fulgent Genetics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Fulgent Genetics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $295M | XXX | $283M | XXX | XXX | XXX |
| Gross Profit | $113M | XXX | $107M | XXX | XXX | XXX |
| Gross Margin | 38% | XXX | 38% | XXX | XXX | XXX |
| EBITDA | -$10.2M | XXX | -$49.0M | XXX | XXX | XXX |
| EBITDA Margin | -3% | XXX | -17% | XXX | XXX | XXX |
| EBIT | -$37.2M | XXX | -$73.9M | XXX | XXX | XXX |
| EBIT Margin | -13% | XXX | -26% | XXX | XXX | XXX |
| Net Profit | -$49.8M | XXX | -$42.7M | XXX | XXX | XXX |
| Net Margin | -17% | XXX | -15% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Fulgent Genetics's stock price is $21.
Fulgent Genetics has current market cap of $630M, and EV of $318M.
See Fulgent Genetics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $318M | $630M | XXX | XXX | XXX | XXX | $0.06 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Fulgent Genetics has market cap of $630M and EV of $318M.
Fulgent Genetics's trades at 1.1x EV/Revenue multiple, and -6.5x EV/EBITDA.
Equity research analysts estimate Fulgent Genetics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Fulgent Genetics has a P/E ratio of -12.6x.
See valuation multiples for Fulgent Genetics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $630M | XXX | $630M | XXX | XXX | XXX |
| EV (current) | $318M | XXX | $318M | XXX | XXX | XXX |
| EV/Revenue | 1.1x | XXX | 1.1x | XXX | XXX | XXX |
| EV/EBITDA | -31.0x | XXX | -6.5x | XXX | XXX | XXX |
| EV/EBIT | -8.5x | XXX | -4.3x | XXX | XXX | XXX |
| EV/Gross Profit | 2.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | -12.6x | XXX | -14.8x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -16.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialFulgent Genetics's last 12 month revenue growth is 10%
Fulgent Genetics's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Fulgent Genetics's rule of 40 is -7% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Fulgent Genetics's rule of X is 21% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Fulgent Genetics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 10% | XXX | 10% | XXX | XXX | XXX |
| EBITDA Margin | -3% | XXX | -17% | XXX | XXX | XXX |
| EBITDA Growth | 69% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -7% | XXX | -7% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 21% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 13% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 17% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 64% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| EZZ Life Science | XXX | XXX | XXX | XXX | XXX | XXX |
| Epigenomics | XXX | XXX | XXX | XXX | XXX | XXX |
| ToolGen | XXX | XXX | XXX | XXX | XXX | XXX |
| 4basebio | XXX | XXX | XXX | XXX | XXX | XXX |
| Genus | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Fulgent Genetics acquired XXX companies to date.
Last acquisition by Fulgent Genetics was XXXXXXXX, XXXXX XXXXX XXXXXX . Fulgent Genetics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Fulgent Genetics founded? | Fulgent Genetics was founded in 2016. |
| Where is Fulgent Genetics headquartered? | Fulgent Genetics is headquartered in United States of America. |
| How many employees does Fulgent Genetics have? | As of today, Fulgent Genetics has 1.3K+ employees. |
| Who is the CEO of Fulgent Genetics? | Fulgent Genetics's CEO is Mr. Ming Hsieh. |
| Is Fulgent Genetics publicy listed? | Yes, Fulgent Genetics is a public company listed on NAS. |
| What is the stock symbol of Fulgent Genetics? | Fulgent Genetics trades under FLGT ticker. |
| When did Fulgent Genetics go public? | Fulgent Genetics went public in 2016. |
| Who are competitors of Fulgent Genetics? | Similar companies to Fulgent Genetics include e.g. EZZ Life Science, Epigenomics, ToolGen, 4basebio. |
| What is the current market cap of Fulgent Genetics? | Fulgent Genetics's current market cap is $630M |
| What is the current revenue of Fulgent Genetics? | Fulgent Genetics's last 12 months revenue is $295M. |
| What is the current revenue growth of Fulgent Genetics? | Fulgent Genetics revenue growth (NTM/LTM) is 10%. |
| What is the current EV/Revenue multiple of Fulgent Genetics? | Current revenue multiple of Fulgent Genetics is 1.1x. |
| Is Fulgent Genetics profitable? | Yes, Fulgent Genetics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Fulgent Genetics? | Fulgent Genetics's last 12 months EBITDA is -$10.2M. |
| What is Fulgent Genetics's EBITDA margin? | Fulgent Genetics's last 12 months EBITDA margin is -3%. |
| What is the current EV/EBITDA multiple of Fulgent Genetics? | Current EBITDA multiple of Fulgent Genetics is -31.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
